Patients with ALK‐mutant advanced lung adenocarcinoma have the highest rate of TE. TE is associated with worse survival across molecular subtypes. These findings should be taken into consideration in decision‐making regarding thromboprophylaxis. READ ARTICLE
Journal of Thrombosis Haemostasis DOI: 10.1111/jth.15215
Authors: Roopkumar J., Poudel S.K., Gervaso L., Reddy C.A., Velcheti V., Pennell N.A., McCrae K.R., Khorana A.A.